Summary:
A randomized, double-blind, double-dummy, active controlled study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of abbv-3373 in subjects with moderate to severe rheumatoid arthritis.
Qualified Participants Must:
Attend all study visits
Be diagnosed with rheumatoid arthritis
Adult male or female
Between 18 and 75 years of age inclusive at screening
Be biologic naive
Incomplete response to methotrexate of 15mg to 25mg and stable for 3 months prior to first dose
Qualified Participants May Receive:
Study treatment at no cost, doctors visit at no cost, blood work results at no cost, receive $40.00 per visit once patient has been qualified and enrolled into the study.